Treatment of Polypoidal Choroidal Vasculopathy in Pachychoroid
Choroidal Neovascularization, Choroid Disease
About this trial
This is an interventional treatment trial for Choroidal Neovascularization focused on measuring pachychoroid, polypoidal choroidal vasculopathy, Aflibercept, photodynamic therapy, Swept source OCT
Eligibility Criteria
Inclusion Criteria:
- presence of haemorrhagic or exudative PCV diagnosed by OCT and ICGA
- Mean central choroidal thickness > 250 µm
Exclusion Criteria:
- ocular comorbidity
- previous cardiovascular events
- different ocular surgical procedures form cataract surgery
Sites / Locations
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Arms of the Study
Arm 1
Experimental
Combined therapy
Treatment consisting in photodynamic therapy (Verteporfin, 6 mg/m2 × Body Surface Area (BSA) = Total Drug Dose; Total Drug Dose ÷ 2.0 mg/mL = Volume of Reconstituted Verteporfin; 30 mL - Volume of Reconstituted Verteporfin = Volume of 5% dextrose in water. Light dose is 50 J/cm2 administered at an intensity of 600 mW/cm2. This dose is administered over 83 seconds) and 3 intravitreal therapy of Aflibercept (2 mg/0,05 ml)monthly, the first of which performed within 7 days from photodynamic therapy.